Z
Zsuzsanna Fabry
Researcher at University of Wisconsin-Madison
Publications - 66
Citations - 2764
Zsuzsanna Fabry is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 27, co-authored 62 publications receiving 2362 citations. Previous affiliations of Zsuzsanna Fabry include University of Wisconsin Hospital and Clinics.
Papers
More filters
Journal ArticleDOI
Intracerebral Mycobacterium bovis bacilli Calmette-Guerin infection-induced immune responses in the CNS☆
JangEun Lee,Changying Ling,Michelle M. Kosmalski,Paul D. Hulseberg,Heidi A. Schreiber,Matyas Sandor,Zsuzsanna Fabry +6 more
TL;DR: Protective immunity is accompanied by accumulation of Foxp3(+)CD4(+) T cells and PD-L2(+) dendritic cells, suggesting that both inflammatory and anti-inflammatory responses develop in the CNS following mycobacterial infection.
Journal ArticleDOI
The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses.
Paul D. Hulseberg,Alla L. Zozulya,H. Hamlet Chu,James A. Triccas,Zsuzsanna Fabry,Matyas Sandor +5 more
TL;DR: It is reported that secreted SIINFEKL from 85B-OVA BCG is presented better than cytoplasmic SIIN FEKL expressed by GFP-OVABCG.
Journal ArticleDOI
Neuroinflammation creates an immune regulatory niche at the meningeal lymphatic vasculature near the cribriform plate
TL;DR: Using single-cell RNA sequencing of meningeal lymphatics near the cribriform plate from healthy and experimental autoimmune encephalomyelitis in the C57BL/6 model, Fabry et al. as discussed by the authors found that lymphangiogenic vessels may acquire an altered phenotype to regulate immunity.
Journal ArticleDOI
Mycobacteria-Induced Suppression of Autoimmunity in the Central Nervous System
TL;DR: Some of the mechanisms by which mycobacterial infection might modulate the clinical course of CNS autoimmunity are reviewed to help develop novel immunotherapeutic tools for treating autoimmune diseases.
Journal Article
Clinical Trial of Helminth-induced Immunomodulatory Therapy (HINT 2) in Relapsing-Remitting Multiple Sclerosis (P3.149)
John O. Fleming,Leslie Hartman,Jane Maksimovic,Sara Nace,Christopher Luzzio,Monica Koehn,Anna Ritter,Todd Risa,Benjamin Lawler,Andrea Maser,Pamela Mundt,Loren A. Rolak,Thomas D. Cook,Aaron S. Field,Zsuzsanna Fabry +14 more
TL;DR: TSO appears safe and well-tolerated in RRMS subjects, and the modest decrease observed in numbers of Gd+ lesions during treatment indicates that further studies if TSO will be required to assess its effectiveness in RR MS.